uniQure N.V. Ordinary Shares vs Vanguard International High Dividend Yield ETF — how do they compare? uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B), while Vanguard International High Dividend Yield ETF trades at $100.51 (market cap $22.80B). The key difference: Vanguard International High Dividend Yield ETF is far larger — about 15.4× uniQure N.V. Ordinary Shares's market cap, and Vanguard International High Dividend Yield ETF is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold uniQure N.V. Ordinary Shares for 0 Days and Vanguard International High Dividend Yield ETF for 51 Days on average.
| QURE | VYMI | |
|---|---|---|
Market Cap | $1.48B | $22.80B |
Volume | 2,488,780 | 740,346 |
Sector | Health | Broad Market / Factor |
52-Week High | $70.59 | $107.13 |
52-Week Low | $9.03 | $84.45 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $728.62M | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VYMI trades at $101.52, up 0.71% with a bearish technical signal from moving averages. The ETF shows strong institutional interest with Envestnet increasing holdings by 22% in Q2 2026. Recent news highlights VYMI's 29% one-year return and 3.61% dividend yield, outperforming peers with a 5-year average annual return of 14.13% according to Seeking Alpha on September 21, 2026.
The outlook remains positive with sector catalysts in financials, energy, and healthcare supporting dividend growth. Key risks include global market volatility and currency exposure. Analyst sentiment leans bullish with VYMI positioned as an attractive international dividend play amid rising global rates.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →